Story

The Full Story — Reckitt Benckiser (RKT.L)

Reckitt's story over the past five years is the slow-motion unwinding of a single bad bet. The £16.6bn acquisition of Mead Johnson Nutrition in 2017 — at 27x EBITDA, the most expensive deal in UK consumer goods history — produced £6.3bn in cumulative goodwill impairments by end-2024 and a NEC litigation overhang that management still cannot quantify. Through three CEO changes, the core Hygiene and Health businesses held their ground, generating over £2bn in free cash flow each year. Management credibility is now improving under Kris Licht, but his "simpler, sharper" framing is the same basic message Reckitt has needed to execute for six years — the difference is that he is actually selling things.

1. The Narrative Arc

The arc runs in three distinct phases: the Kapoor expansion era (ending 2019 with the MJN millstone), the Narasimhan restructuring that ran out of time (2019–2022), and the Licht retrenchment (2023–present). The inflection points that matter most are not the earnings beats but the silences: six years of holding MJN goodwill at full value while fundamentals deteriorated, and ongoing opacity around NEC litigation reserves.

2. What Management Emphasised — and Then Stopped Emphasising

Parser Error: syntax error at or near "order"

LINE 42: order by topic, year
         ^

LINE 42: order by topic, year
         ^

Three patterns stand out. First, "Sustainable LFL Growth" has been constant at intensity 4 across every year regardless of actual delivery — it is less a strategic message than a mantra. Second, "Nutrition / IFCN Growth" faded from steady emphasis to near-silence between 2022 and 2024; the silence is more revealing than anything said explicitly. Third, "IFCN Strategic Review" and "NEC Litigation" emerged suddenly in 2023–2024 from zero — these were not gradually increasing risks, they were topics management avoided as long as possible.

3. Risk Evolution

Parser Error: syntax error at or near "order"

LINE 37: order by risk, year
         ^

LINE 37: order by risk, year
         ^

Input cost inflation peaked in 2022 and faded — Reckitt's pricing power absorbed most of it. The more significant pattern is the replacement of input cost risk by litigation and portfolio risk: NEC Litigation jumped from zero to the highest severity in two years, while Goodwill Impairment Risk ran hot in 2023–2024 before beginning to normalise (most of the MJN/IFCN impairment has now been taken). Leadership instability, the dominant anxiety in 2022, has materially receded under Licht.

Goodwill fell from £17.9bn to £11.2bn in two steps. The remaining £11.2bn still carries significant IFCN intangible value; future impairments are possible depending on IFCN US exit execution and NEC litigation outcomes.

4. How They Handled Bad News

The pattern across three distinct crisis episodes is consistent: initial under-disclosure, eventual forced acknowledgement, and then repositioning as "decisive action."

The MJN acquisition (2017–2024): Six years of silence. The deal was closed at 27x EBITDA with management describing infant formula as "a high-growth, defensible category." US market share losses began almost immediately. Birth rates fell. China lockdowns hurt volumes. By 2021, IFCN LFL growth was already negative. Management continued to describe IFCN as a "core pillar" through 2022. The first impairment came in FY2023 (£2.5bn); a larger one followed in FY2024 (£3.8bn). Total cumulative impairment: £6.3bn on a £13.2bn purchase price. No management team wrote down a major acquisition voluntarily — accounting rules require impairment when recoverable value falls below carrying value, but management's public commentary stayed far more optimistic than the underlying economics warranted.

Narasimhan departure (September 2022): The ambiguous exit. Narasimhan left "for personal and family reasons" — a statement markets found implausible given he was announced as the new Starbucks CEO within days. JP Morgan noted his departure came "just when investor confidence in the group's turnaround was improving." Whether this was a pull factor (Starbucks offer) or a push factor (board dynamics around IFCN strategy) remains unresolved. What it did was reset the management credibility clock to zero at the worst possible time: goodwill impairments were about to begin.

NEC litigation: Ongoing opacity. Thousands of US cases allege Mead Johnson's Enfamil premature infant formula contributed to necrotizing enterocolitis (NEC). Large verdicts have been returned against both Reckitt and Abbott. Management has declined to disclose a specific litigation provision. This is the most significant outstanding disclosure gap in the Reckitt narrative — investors cannot model the residual liability.

5. Guidance Track Record

The FY2024 LFL miss was the most damaging single event in the recent track record. Management guided for 2–4% growth; IFCN's -9.8% LFL dragged the group to -0.5%. The EBITDA margin miss (23.3% vs ~26% expected) was equally significant and was entirely IFCN-driven. The FY2023 delivery (3.0% vs 3–5% guidance) was technically within range but at the lowest end — a soft beat, not a real one.

Score rationale (5/10): The FCF franchise is real and has been consistently delivered — that is worth 3 points on its own. Core Hygiene and Health brands genuinely have pricing power and category leadership. But: two consecutive years of large goodwill impairments on a deal that was obviously deteriorating for years; three CEO changes in three years; ongoing NEC provision opacity; and a track record of holding an optimistic IFCN narrative far past the point where the numbers justified it. Licht's messaging is more credible than his predecessors', and the portfolio actions are real — but credibility is rebuilt through delivery, not intention.

6. What the Story Is Now

Reckitt in 2025–2026 is a simpler business than it was in 2020 — by design. The Licht strategy is visible and coherent: exit Nutrition (IFCN China sold for ~$1.3bn, US IFCN under review), exit Essential Home (Air Wick divestiture underway), and concentrate the full organisation on Hygiene (Dettol, Lysol, Finish) and Health (Nurofen, Mucinex, Gaviscon, Durex). The ~$4.8bn of planned disposals will structurally de-lever and simplify. At CAGNY 2026, Licht used the phrase "simpler, sharper" — a clean articulation of a strategy that has been overdue for the better part of a decade.

The reader should believe: the Hygiene/Health franchise is genuinely durable, FCF will remain above £2bn unless NEC provisions arrive, and Licht's portfolio simplification is the right strategy executed at least two years late.

The reader should discount: any near-term multiple re-rating until NEC litigation is quantified; guidance on EBITDA margin recovery pace (FY2024 missed the equivalent prior-year implied guidance by 270bps); and the "simpler, sharper" narrative until the US IFCN disposal is completed and the NEC reserve is disclosed.